First Capital Advisors Group LLC. Has $1.31 Million Holdings in AbbVie Inc (ABBV)
First Capital Advisors Group LLC. lowered its position in shares of AbbVie Inc (NYSE:ABBV) by 20.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 14,687 shares of the company’s stock after selling 3,709 shares during the period. First Capital Advisors Group LLC.’s holdings in AbbVie were worth $1,305,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Acropolis Investment Management LLC bought a new stake in shares of AbbVie during the second quarter valued at approximately $106,000. Hudock Capital Group LLC raised its position in shares of AbbVie by 109.5% during the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after buying an additional 806 shares during the last quarter. Ffcm LLC raised its position in shares of AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after buying an additional 963 shares during the last quarter. Bristlecone Advisors LLC bought a new stake in shares of AbbVie during the third quarter valued at approximately $113,000. Finally, BDO Wealth Advisors LLC bought a new stake in shares of AbbVie during the second quarter valued at approximately $115,000. 69.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of AbbVie Inc (ABBV) opened at $99.69 on Thursday. AbbVie Inc has a 1 year low of $59.27 and a 1 year high of $101.28. The firm has a market cap of $158,920.00, a price-to-earnings ratio of 24.20, a P/E/G ratio of 1.20 and a beta of 1.53. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. During the same quarter in the previous year, the business posted $1.21 earnings per share. AbbVie’s quarterly revenue was up 8.8% on a year-over-year basis. analysts forecast that AbbVie Inc will post 5.55 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.85%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is presently 62.14%.
Several equities research analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating on shares of AbbVie in a research report on Friday, October 13th. Jefferies Group lifted their price objective on shares of AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, October 16th. BMO Capital Markets reiterated a “hold” rating and set a $84.00 price objective on shares of AbbVie in a research report on Tuesday, November 21st. Piper Jaffray Companies lifted their price objective on shares of AbbVie to $115.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Finally, Leerink Swann reduced their price objective on shares of AbbVie from $108.00 to $107.00 and set an “outperform” rating on the stock in a research report on Monday, October 30th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie presently has an average rating of “Buy” and an average target price of $100.94.
In other AbbVie news, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the transaction, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now directly owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The disclosure for this sale can be found here. Insiders have sold 494,676 shares of company stock valued at $47,237,938 over the last ninety days. 0.23% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/first-capital-advisors-group-llc-has-1-31-million-holdings-in-abbvie-inc-abbv/1802430.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with Analyst Ratings Network's FREE daily email newsletter.